Articles from Kiyatec

Kiyatec, a leader in functional oncology testing with its proprietary 3D Predict™ platform, today announced it has closed a strategic investment round led by MBD, a South Korea-based technology leader. This new investment solidifies a strategic commercial partnership aimed at leveraging MBD’s automated platform technology to rapidly scale Kiyatec’s U.S. testing capabilities and accelerate the launch of its diagnostic panels for multiple cancer types along with new AI tools.

Kiyatec Inc., a leader in advancing patient-specific cancer diagnostics, proudly announces its laboratory’s accreditation by the College of American Pathologists (CAP) and receipt of New York State approval for its groundbreaking 3D Predict test. These achievements underscore Kiyatec’s commitment to delivering high-quality, innovative diagnostic solutions that support personalized cancer care.

Kiyatec, leaders in functional precision oncology, today announced the publication of a pivotal study in Scientific Reports highlighting the impact of the 3D Predict Glioma test on improving survival outcomes for patients with HGG. The study, titled “Functional prediction of response to therapy prior to therapeutic intervention is associated with improved survival in patients with high-grade glioma,” presents compelling evidence that the 3D Predict Glioma test can significantly extend progression-free survival and overall survival in patients by accurately predicting their response to the standard chemotherapeutic regimen.

Kiyatec, a leading biotechnology company specializing in 3D cell culture technology, is pleased to announce the promotion of Eric Perreault to the position of chief executive officer (CEO). As CEO, Eric will continue to lead Kiyatec in its mission to revolutionize cancer care by harnessing the power of functional precision medicine with its KIYA-Predict™ and 3D Predict™ platforms. He succeeds Matt Gevaert, PhD, who after more than 15 years as CEO will remain a member of Kiyatec’s Board of Directors.

Kiyatec, a leading functional precision oncology company specializing in 3D cell culture technology and delivering evidence of therapeutic response in the oncology space, is pleased to announce that Mark Capone, former CEO of Myriad Genetics, has joined its team as a strategic advisor.

Kiyatec, a leading biotechnology company specializing in 3D cell culture technologies, is pleased to announce the appointment of Eric Perreault to the position of President. Additionally, the company appoints Tessa DesRochers, PhD, Chief Scientific Officer to Vice President of Pre-Clinical Services. These strategic appointments demonstrate Kiyatec’s commitment to its mission of providing confidence to patients, oncologists, and pharmaceutical companies in their life-changing cancer therapy decisions through its functional precision assay, 3D Predict™, which accurately predicts patient-specific therapeutic response and nonresponse before treatment begins.

Kiyatec, the leader in clinically correlated functional precision oncology, and XenoSTART, the worldwide leader in patient derived xenograft model development, have formally announced their ongoing collaboration to help biopharma more rapidly assess efficacy with XenoSTART’s Patient Derived Xenograft (XPDX) models, using Kiyatec’s ex vivo 3D spheroid screening platform. This collaboration using Kiyatec’s ex vivo spheroid platform aligns with XenoSTART’s initiatives to deliver advanced in vivo mouse models to save time and expedite the drug development process.

AstraZeneca and Kiyatec, the leader in clinically correlated functional precision oncology, have entered into a multifaceted research agreement to assess therapeutic efficacy of undisclosed preclinical assets using Kiyatec’s 3D spheroid screening platform, KIYA-PredictTM. The agreement to utilize Kiyatec’s spheroid platform aligns with AstraZeneca’s leadership and track record of successfully implementing novel, cutting edge oncology solutions with outside partners to productively develop and commercialize novel cancer therapeutics.

Kiyatec, the leader in clinically correlated, published functional precision oncology technology, today announced that two abstracts were accepted for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting to be held in Orlando, Florida from April 14 – 19, 2023.

Kiyatec, the leader in clinically correlated, published functional precision oncology evidence today announced that CEO Matt Gevaert, Ph.D., will participate as a panelist in the “Accelerating Drug Development” session at the Longwood Healthcare Leaders Fall Webconference on Thursday, September 22, 2022, at 8:50 AM Eastern Time. Details regarding this and future Longwood Healthcare Leaders events can be found at https://www.longwoodhealthcareleaders.com/. The Longwood Healthcare Leaders conferences serve to facilitate the acceleration of life sciences discoveries to benefit patients.

Kiyatec, the leader in clinically correlated, published functional precision oncology evidence today announced the company is sponsoring and exhibiting at the virtual American Brain Tumor Association 2022 National Conference September 9-10, 2022. Details regarding this event can be found here: https://www.abta.org/national-conference-2022/

Kiyatec, a leader in functional precision oncology, announced new clinical evidence of its proprietary ex vivo 3D cell culture technology use in high-grade glioma will be presented at ASCO 2022. As a first-time ASCO presenter and exhibitor, Kiyatec will present its Clinical Services and Drug Development Services capabilities at ASCO’s first-ever Innovation Hub at kiosk #IH01. The ASCO meeting will be held in Chicago June 3-7, 2022.

Headline of release should read: KIYATEC and ACCRF Joint Abstract at AACR Highlights Use of KIYA-PREDICT™ Drug Response Platform in ACC (instead of KIYATEC and AACR Joint Abstract at AACR Highlights Use of KIYA-PREDICT™ Drug Response Platform in ACC).

KIYATEC, the leader in clinically correlated, published functional precision oncology technology and the Adenoid Cystic Carcinoma Research Foundation (ACCRF) today announced their jointly-authored abstract will be presented as a poster at the American Association for Cancer Research® Annual Meeting on April 10th, 2022 1:30pm – 5:00pm CST among the 3D Models and Microfluidics, Section 9 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

KIYATEC, the leader in clinically correlated, published functional precision oncology technology today announced that CEO Matt Gevaert, Ph.D., will present virtually at the KeyBanc Capital Markets’ Life Sciences & MedTech Investor Forum on Wednesday, March 23, 2022, at 1:30 PM Eastern Time. KIYATEC’s participation includes virtual one-on-one meetings with investors during the two-day event which begins Tuesday, March 22nd.

KIYATEC, the leader in clinically correlated, published functional precision oncology technology today announced two key appointments as the Company builds utilization of clinical 3D Predict™ assays and grows its pharmaceutical services portfolio for KIYA-PREDICT™. KIYATEC is pleased to welcome Bruce Yeager as Vice President Market Access & Reimbursement effective March 21, 2022, and Steven Holshouser, Ph.D., as Director, Business Development, effective March 8, 2022.

KIYATEC, the leader in clinically correlated, published functional precision oncology technology today announced that six abstracts were accepted for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022. The meeting will be held in New Orleans from April 8 – 13, 2022.

KIYATEC is pleased to announce today a significant expansion of its operations at 2 N Main as the first anchor company in downtown Greenville’s new Innovation District. Greenville is already a top choice for growth investments across many industries, offering a highly educated labor force, excellent quality of life, a competitive cost profile and a business-friendly environment. This new Innovation District makes Greenville one of just a handful of U.S. cities to feature life science laboratory facilities with Main Street addresses.

The functional precision oncology company KIYATEC, Inc. announced today the addition of Chief Commercial Officer, Stacy Chick, to their Executive Team. Stacy brings over 30 years of successful life sciences commercialization experience in pharmaceutical and oncology molecular diagnostic sales, marketing, market access and reimbursement, business development and policy. Most recently, Stacy served as US Commercial Advisor to several global life sciences companies, investors, and boards. As CCO at KIYATEC she is responsible for building and leading the commercial strategies for clinical testing, beginning with the 3D PredictTM tests.

Functional precision oncology innovator KIYATEC announced today that it is initiating use of the 3D Predict™ Glioma test outside of its 3D-PREDICT clinical study. Recently published peer-reviewed data demonstrated successful use of this test for patients with either newly diagnosed or recurrent high-grade gliomas, which includes glioblastoma (GBM).

KIYATEC, Inc announced today that it secured a $2.5 million investment from Boston-based healthcare service and technology venture capital fund Seae Ventures. The fund’s focus in disruptive healthcare technologies aligns with KIYATEC’s goal to fundamentally change the way cancer drugs are selected by providing oncologists with patient-specific evidence of response, prior to treatment initiation.